Another massive opportunity presented here. Would be very open to management replicating this using Zantrene. Take $1m from the est $6-8m of BB funds. On the surface it would seem high in potential return in terms of prioritising what we spend money on. The Monash work will be interesting insight into what we could do outside the oncology space.
Ann: Appendix 3Y - Dr Daniel Tillett, page-37
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.75 |
Change
0.010(0.57%) |
Mkt cap ! $298.0M | |||
| Open | High | Low | Value | Volume |
| $1.73 | $1.83 | $1.73 | $272.0K | 152.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9998 | $1.75 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.79 | 2000 | 1 |
View Market Depth
| Last trade - 16.10pm 09/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |